Brent A Stanfield1,2,3, Todd Purves1,2,4, Scott Palmer1,5,6, Bruce Sullenger1,2, Karen Welty-Wolf1,5, Krista Haines1,2,3, Suresh Agarwal1,2,3, George Kasotakis1,2,3. 1. Duke University Medical Center, Durham, North Carolina, United States of America. 2. Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America. 3. Division of Trauma, Acute and Critical Care Surgery, Duke University Medical Center, Durham, North Carolina, United States of America. 4. Division of Urology, Duke University Medical Center, Durham, North Carolina, United States of America. 5. Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America. 6. Duke Clinical Research Institute, Durham, North Carolina, United States of America.
Abstract
INTRODUCTION: Anti-inflammatory cytokine IL-10 suppresses pro-inflammatory IL-12b expression after Lipopolysaccharide (LPS) stimulation in colonic macrophages, as part of the innate immunity Toll-Like Receptor (TLR)-NF-κB activation system. This homeostatic mechanism limits excess inflammation in the intestinal mucosa, as it constantly interacts with the gut flora. This effect is reversed with Histone Deacetylase 3 (HDAC3), a class I HDAC, siRNA, suggesting it is mediated through HDAC3. Given alveolar macrophages' prominent role in Acute Lung Injury (ALI), we aim to determine whether a similar regulatory mechanism exists in the typically sterile pulmonary microenvironment. METHODS: Levels of mRNA and protein for IL-10, and IL-12b were determined by qPCR and ELISA/Western Blot respectively in naïve and LPS-stimulated alveolar macrophages. Expression of the NF-κB intermediaries was also similarly assessed. Experiments were repeated with AS101 (an IL-10 protein synthesis inhibitor), MS-275 (a selective class 1 HDAC inhibitor), or both. RESULTS: LPS stimulation upregulated all proinflammatory mediators assayed in this study. In the presence of LPS, inhibition of IL-10 and/or class 1 HDACs resulted in both synergistic and independent effects on these signaling molecules. Quantitative reverse-transcriptase PCR on key components of the TLR4 signaling cascade demonstrated significant diversity in IL-10 and related gene expression in the presence of LPS. Inhibition of IL-10 secretion and/or class 1 HDACs in the presence of LPS independently affected the transcription of MyD88, IRAK1, Rela and the NF-κB p50 subunit. Interestingly, by quantitative ELISA inhibition of IL-10 secretion and/or class 1 HDACs in the presence of LPS independently affected the secretion of not only IL-10, IL-12b, and TNFα, but also proinflammatory mediators CXCL2, IL-6, and MIF. These results suggest that IL-10 and class 1 HDAC activity regulate both independent and synergistic mechanisms of proinflammatory cytokine/chemokine signaling. CONCLUSIONS: Alveolar macrophages after inflammatory stimulation upregulate both IL-10 and IL-12b production, in a highly class 1 HDAC-dependent manner. Class 1 HDACs appear to help maintain the balance between the pro- and anti-inflammatory IL-12b and IL-10 respectively. Class 1 HDACs may be considered as targets for the macrophage-initiated pulmonary inflammation in ALI in a preclinical setting.
INTRODUCTION: Anti-inflammatory cytokine IL-10 suppresses pro-inflammatory IL-12b expression after Lipopolysaccharide (LPS) stimulation in colonic macrophages, as part of the innate immunity Toll-Like Receptor (TLR)-NF-κB activation system. This homeostatic mechanism limits excess inflammation in the intestinal mucosa, as it constantly interacts with the gut flora. This effect is reversed with Histone Deacetylase 3 (HDAC3), a class I HDAC, siRNA, suggesting it is mediated through HDAC3. Given alveolar macrophages' prominent role in Acute Lung Injury (ALI), we aim to determine whether a similar regulatory mechanism exists in the typically sterile pulmonary microenvironment. METHODS: Levels of mRNA and protein for IL-10, and IL-12b were determined by qPCR and ELISA/Western Blot respectively in naïve and LPS-stimulated alveolar macrophages. Expression of the NF-κB intermediaries was also similarly assessed. Experiments were repeated with AS101 (an IL-10 protein synthesis inhibitor), MS-275 (a selective class 1 HDAC inhibitor), or both. RESULTS:LPS stimulation upregulated all proinflammatory mediators assayed in this study. In the presence of LPS, inhibition of IL-10 and/or class 1 HDACs resulted in both synergistic and independent effects on these signaling molecules. Quantitative reverse-transcriptase PCR on key components of the TLR4 signaling cascade demonstrated significant diversity in IL-10 and related gene expression in the presence of LPS. Inhibition of IL-10 secretion and/or class 1 HDACs in the presence of LPS independently affected the transcription of MyD88, IRAK1, Rela and the NF-κB p50 subunit. Interestingly, by quantitative ELISA inhibition of IL-10 secretion and/or class 1 HDACs in the presence of LPS independently affected the secretion of not only IL-10, IL-12b, and TNFα, but also proinflammatory mediators CXCL2, IL-6, and MIF. These results suggest that IL-10 and class 1 HDAC activity regulate both independent and synergistic mechanisms of proinflammatory cytokine/chemokine signaling. CONCLUSIONS: Alveolar macrophages after inflammatory stimulation upregulate both IL-10 and IL-12b production, in a highly class 1 HDAC-dependent manner. Class 1 HDACs appear to help maintain the balance between the pro- and anti-inflammatory IL-12b and IL-10 respectively. Class 1 HDACs may be considered as targets for the macrophage-initiated pulmonary inflammation in ALI in a preclinical setting.
Authors: Michael T Lotze; Herbert J Zeh; Anna Rubartelli; Louis J Sparvero; Andrew A Amoscato; Newell R Washburn; Michael E Devera; Xiaoyan Liang; Mahmut Tör; Timothy Billiar Journal: Immunol Rev Date: 2007-12 Impact factor: 12.988
Authors: G R Bernard; J M Luce; C L Sprung; J E Rinaldo; R M Tate; W J Sibbald; K Kariman; S Higgins; R Bradley; C A Metz Journal: N Engl J Med Date: 1987-12-17 Impact factor: 91.245
Authors: Dianhua Jiang; Jiurong Liang; Juan Fan; Shuang Yu; Suping Chen; Yi Luo; Glenn D Prestwich; Marcella M Mascarenhas; Hari G Garg; Deborah A Quinn; Robert J Homer; Daniel R Goldstein; Richard Bucala; Patty J Lee; Ruslan Medzhitov; Paul W Noble Journal: Nat Med Date: 2005-10-23 Impact factor: 53.440
Authors: Gustaf Christoffersson; Evelina Vågesjö; Jennifer Vandooren; Majken Lidén; Sara Massena; Rachel B Reinert; Marcela Brissova; Alvin C Powers; Ghislain Opdenakker; Mia Phillipson Journal: Blood Date: 2012-09-10 Impact factor: 22.113
Authors: Curtis T Rueden; Johannes Schindelin; Mark C Hiner; Barry E DeZonia; Alison E Walter; Ellen T Arena; Kevin W Eliceiri Journal: BMC Bioinformatics Date: 2017-11-29 Impact factor: 3.169
Authors: Karen A Cavassani; Makoto Ishii; Haitao Wen; Matthew A Schaller; Pamela M Lincoln; Nicholas W Lukacs; Cory M Hogaboam; Steven L Kunkel Journal: J Exp Med Date: 2008-10-06 Impact factor: 14.307
Authors: Maria Adriana Neag; Andrei Otto Mitre; Adrian Catinean; Anca Dana Buzoianu Journal: World J Gastroenterol Date: 2021-11-21 Impact factor: 5.742
Authors: Matthew DeBerge; Connor Lantz; Shirley Dehn; David P Sullivan; Anja M van der Laan; Hans W M Niessen; Margaret E Flanagan; Daniel J Brat; Matthew J Feinstein; Sunjay Kaushal; Lisa D Wilsbacher; Edward B Thorp Journal: J Exp Med Date: 2021-07-29 Impact factor: 14.307